SPL
STARPHARMA HOLDINGS ORDINARYStarpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
SPL
SPL
STARPHARMA HOLDINGS ORDINARY
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 0.11% | — |
| 10 July | 0.11% | — |
| 9 July | 0.11% | — |
| 8 July | 0.11% | — |
| 7 July | 0.11% | — |
| 6 July | 0.11% | — |
| 3 July | 0.11% | — |
| 2 July | 0.11% | — |
| 1 July | 0.10% | — |
Starpharma Holdings (SPL) Short Interest Summary
Starpharma Holdings (SPL) currently has 0.11% of its shares sold short (455 thousand shares, worth approximately $324K), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes SPL the #455 most shorted stock on the ASX most shorted list. Short interest in SPL is down 0.00% over the past week and down 0.01% over the past month. SPL is part of the Health Care sector on the ASX.
Recent SPL Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 0.11% | 0.5M | $0.71 |
| 10 July 2026 | 0.11% | 0.5M | $0.72 |
| 9 July 2026 | 0.11% | 0.5M | $0.73 |
| 8 July 2026 | 0.11% | 0.5M | $0.71 |
| 7 July 2026 | 0.11% | 0.5M | $0.71 |
| 6 July 2026 | 0.11% | 0.5M | $0.73 |
| 3 July 2026 | 0.11% | 0.5M | $0.74 |
| 2 July 2026 | 0.11% | 0.5M | $0.71 |
| 1 July 2026 | 0.10% | 0.4M | $0.71 |
| 30 June 2026 | 0.08% | 0.4M | $0.70 |
SPL Short Selling — Frequently Asked Questions
What is Starpharma Holdings (SPL)'s current short interest?
Starpharma Holdings (SPL) currently has a short interest of 0.11% of total shares outstanding. This means 0.11% of SPL's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is SPL heavily shorted on the ASX?
SPL has a relatively low short interest of 0.11%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for SPL investors?
Short interest in SPL shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.11%, SPL's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this SPL short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for SPL.